Almirall, GW Pharma sales and marketing update

Almirall and GW added Mexico to a 2005 deal granting Almirall exclusive marketing rights to Sativex in the EU, excluding the U.K. GW will receive a milestone payment of €12 million ($15.7 million). The sublingual cannabis extract spray containing tetrahydrocannabinol (THC) and cannabidiol (CBD) is approved to treat spasticity due to multiple sclerosis in Austria, Spain, Germany, Demark and New Zealand. ...